Topical sirolimus for management of refractory oral chronic graft‐versus‐host disease
Oral Diseases2020Vol. 27(6), pp. 1451–1454
Citations Over Time
Abstract
None to declare.
Related Papers
- → The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children(2014)72 cited
- Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.(2000)
- → A successful tale of sirolimus treatment in refractory vascular tumors(2022)2 cited
- Application of sirolimus in drug-eluting stent(2009)
- Pharmacokinetics of Sirolimus in Subjects Treated with Intravitreal Sirolimus in the SAVE-2 Study: Sirolimus As Therapeutic Approach to UVEitis – Protocol 2 with Two Doses of Intravitreal Sirolimus(2018)